Current status of estrogen and progesterone receptors in breast cancer, Cancer, vol.196, issue.6, pp.2934-2947, 1977. ,
DOI : 10.1002/1097-0142(197706)39:6<2934::AID-CNCR2820390680>3.0.CO;2-P
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases, Journal of Clinical Oncology, vol.21, issue.10, pp.1973-1979, 2003. ,
DOI : 10.1200/JCO.2003.09.099
Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities, Clinical Cancer Research, vol.13, issue.7, pp.1950-1954, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2540
Pathways to tamoxifen resistance, Cancer Letters, vol.256, issue.1, pp.1-24, 2007. ,
DOI : 10.1016/j.canlet.2007.03.016
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533271
CYP2D6 and tamoxifen: DNA matters in breast cancer, Nature Reviews Cancer, vol.58, issue.8, pp.576-586, 2009. ,
DOI : 10.1038/nrc2683
Estrogen Receptors: How Do They Signal and What Are Their Targets, Physiological Reviews, vol.87, issue.3, pp.905-931, 2007. ,
DOI : 10.1152/physrev.00026.2006
HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention, Oncogene, vol.265, issue.37, pp.5310-5318, 2007. ,
DOI : 10.1016/S1535-6108(04)00114-X
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men, Nature Reviews Molecular Cell Biology, vol.110, issue.3, pp.206-218, 2008. ,
DOI : 10.1038/nrm2346
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8???substrate complex, EMBO reports, vol.19, issue.9, pp.879-884, 2007. ,
DOI : 10.1016/S0959-437X(03)00015-7
Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity, Journal of Biological Chemistry, vol.283, issue.17, pp.11355-11363, 2008. ,
DOI : 10.1074/jbc.M707362200
Novel Structural Insights into Class I and II Histone Deacetylases, Current Topics in Medicinal Chemistry, vol.9, issue.3, pp.235-240, 2009. ,
DOI : 10.2174/156802609788085304
The many roles of histone deacetylases in development and physiology: implications for disease and therapy, Nature Reviews Genetics, vol.144, issue.1, pp.32-42, 2009. ,
DOI : 10.1038/nrg2485
HDAC family: What are the cancer relevant targets?, Cancer Letters, vol.277, issue.1, pp.8-21, 2009. ,
DOI : 10.1016/j.canlet.2008.08.016
HDAC expression and clinical prognosis in human malignancies, Cancer Letters, vol.280, issue.2, pp.168-176, 2009. ,
DOI : 10.1016/j.canlet.2008.10.047
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug, Nature Biotechnology, vol.125, issue.1, pp.84-90, 2007. ,
DOI : 10.1038/nbt1272
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents, Journal of Hematology & Oncology, vol.3, issue.1, 2010. ,
DOI : 10.1186/1756-8722-3-5
URL : http://doi.org/10.1186/1756-8722-3-5
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer, Journal of Hematology & Oncology, vol.2, issue.1, 2009. ,
DOI : 10.1186/1756-8722-2-22
Histone deacetylase inhibitors: Multifunctional anticancer agents, Cancer Treatment Reviews, vol.32, issue.3, pp.157-165, 2006. ,
DOI : 10.1016/j.ctrv.2005.12.006
Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, vol.3, issue.37, pp.5541-5552, 2007. ,
DOI : 10.1016/j.bbrc.2005.12.144
Anticancer activities of histone deacetylase inhibitors, Nature Reviews Drug Discovery, vol.106, issue.9, pp.769-784, 2006. ,
DOI : 10.1038/nrd2133
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nature Reviews Cancer, vol.105, issue.1, pp.38-51, 2006. ,
DOI : 10.1038/nrc1779
Isoform-specific histone deacetylase inhibitors: The next step?, Cancer Letters, vol.280, issue.2, pp.211-221, 2009. ,
DOI : 10.1016/j.canlet.2009.02.013
Biomarkers for predicting clinical responses to HDAC inhibitors, Cancer Letters, vol.280, issue.2, pp.177-183, 2009. ,
DOI : 10.1016/j.canlet.2009.03.016
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker, British Journal of Cancer, vol.8, issue.7, pp.1044-1050, 2009. ,
DOI : 10.1038/81671
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous Tcell lymphoma HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy, Clinical Cancer Research Proceedings of the National Academy of Sciences of the United States of America, vol.14, issue.107 14, pp.4500-4510, 2008. ,
Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression, Clinical Cancer Research, vol.15, issue.9, pp.3163-3171, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2319
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746548
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis, Breast Cancer Research and Treatment, vol.107, issue.1, pp.15-23, 2005. ,
DOI : 10.1007/s10549-004-1668-2
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*, Breast Cancer Research and Treatment, vol.279, issue.1, pp.11-16, 2005. ,
DOI : 10.1007/s10549-005-6001-1
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes, Molecular Cancer Research, vol.7, issue.4, pp.511-522, 2009. ,
DOI : 10.1158/1541-7786.MCR-08-0107
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis, JNCI Journal of the National Cancer Institute, vol.98, issue.4, pp.262-272, 2006. ,
DOI : 10.1093/jnci/djj052
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity, Proceedings of the National Academy of Sciences, vol.104, issue.18, pp.7564-7569, 2007. ,
DOI : 10.1073/pnas.0702507104
Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, vol.6, issue.7074, pp.353-357, 2006. ,
DOI : 10.1038/nature04296
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies, Cancer Cell, vol.10, issue.6, pp.529-541, 2006. ,
DOI : 10.1016/j.ccr.2006.10.009
URL : http://doi.org/10.1016/j.ccr.2006.10.009
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns, Cancer Research, vol.61, issue.16, pp.5979-5984, 2001. ,
Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer, Cancer Research, vol.66, issue.21, pp.10292-10301, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-4414
Genes that mediate breast cancer metastasis to lung, Nature, vol.436, issue.7050, pp.518-524, 2005. ,
DOI : 10.1038/nature03799
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1283098
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, 1999. ,
DOI : 10.1056/NEJMoa021967
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, The Lancet, vol.365, issue.9460, pp.671-679, 2005. ,
DOI : 10.1016/S0140-6736(05)70933-8
Predicting the clinical status of human breast cancer by using gene expression profiles, Proceedings of the National Academy of Sciences, vol.98, issue.20, pp.11462-11467, 2001. ,
DOI : 10.1073/pnas.201162998
A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors, Clinical Cancer Research, vol.12, issue.11, pp.3288-3296, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1530
A stromal gene signature associated with inflammatory breast cancer, International Journal of Cancer, vol.100, issue.6, pp.1324-1332, 2008. ,
DOI : 10.1002/ijc.23237
Gene-Expression Profiles in Hereditary Breast Cancer, New England Journal of Medicine, vol.344, issue.8, pp.539-548, 2001. ,
DOI : 10.1056/NEJM200102223440801
Predicting features of breast cancer with gene expression patterns, Breast Cancer Research and Treatment, vol.93, issue.12, pp.191-201, 2008. ,
DOI : 10.1007/s10549-007-9596-6
Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000. ,
DOI : 10.1038/35021093
X chromosomal abnormalities in basal-like human breast cancer, Cancer Cell, vol.9, issue.2, pp.121-132, 2006. ,
DOI : 10.1016/j.ccr.2006.01.013
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001. ,
DOI : 10.1073/pnas.191367098
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors, Proceedings of the National Academy of Sciences, vol.99, issue.20, pp.12963-12968, 2002. ,
DOI : 10.1073/pnas.162471999
Repeated observation of breast tumor subtypes in independent gene expression data sets, Proceedings of the National Academy of Sciences, vol.100, issue.14, pp.8418-8423, 2003. ,
DOI : 10.1073/pnas.0932692100
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series, Clinical Cancer Research, vol.13, issue.11, pp.3207-3214, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2765
Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers, Clinical Cancer Research, vol.12, issue.15, pp.4533-4544, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2339
URL : https://hal.archives-ouvertes.fr/hal-01431971
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, vol.24, issue.26, pp.4236-4244, 2006. ,
DOI : 10.1200/JCO.2006.05.6861
Gene expression predictors of breast cancer outcomes, The Lancet, vol.361, issue.9369, pp.1590-1596, 2003. ,
DOI : 10.1016/S0140-6736(03)13308-9
High-resolution genomic and expression analyses of copy number alterations in breast tumors, Genes, Chromosomes and Cancer, vol.22, issue.6, pp.530-542, 2008. ,
DOI : 10.1002/gcc.20558
A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling, British Journal of Cancer, vol.2001, issue.8, pp.1327-1335, 2008. ,
DOI : 10.1158/1078-0432.CCR-04-0085
Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proceedings of the National Academy of Sciences, vol.100, issue.18, pp.10393-10398, 2003. ,
DOI : 10.1073/pnas.1732912100
Different Gene Expression Patterns in Invasive Lobular and Ductal Carcinomas of the Breast, Molecular Biology of the Cell, vol.15, issue.6, pp.2523-2536, 2004. ,
DOI : 10.1091/mbc.E03-11-0786
HDAC6 Expression Is Correlated with Better Survival in Breast Cancer, Clinical Cancer Research, vol.10, issue.20, pp.6962-6968, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0455
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer, Oncogene, vol.10, issue.28, pp.4531-4539, 2005. ,
DOI : 10.1038/sj.onc.1208646
Highresolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer, Genome Biology, vol.8, issue.10 R215, 2007. ,
Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer, Cancer Research, vol.68, issue.22, pp.9532-9540, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-3082
Development of cDNA microarray for expression profiling of estrogen-responsive genes, Journal of Molecular Endocrinology, vol.29, issue.2, pp.175-192, 2002. ,
DOI : 10.1677/jme.0.0290175
The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis, Cancer Research, vol.68, issue.18, pp.7561-7569, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-0188
Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes, Cancer Science, vol.61, issue.6, pp.496-502, 2004. ,
DOI : 10.1073/pnas.201162998
An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1, Gastroenterology, vol.135, issue.5, pp.1654-1664, 2008. ,
DOI : 10.1053/j.gastro.2008.07.078
Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells, Clinical Cancer Research, vol.6, issue.11, pp.4334-4342, 2000. ,
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo, Clinical Cancer Research, vol.7, issue.4, pp.971-976, 2001. ,
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells, Biochemical Pharmacology, vol.68, issue.6, pp.1239-1246, 2004. ,
DOI : 10.1016/j.bcp.2004.04.031
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells, Journal of Endocrinology, vol.179, issue.1, pp.41-53, 2003. ,
DOI : 10.1677/joe.0.1790041
Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells, Molecular Cancer, vol.5, issue.8, 2006. ,
Histone deacetylase inhibitors: Signalling towards p21cip1/waf1, The International Journal of Biochemistry & Cell Biology, vol.39, issue.7-8, pp.1367-1374, 2007. ,
DOI : 10.1016/j.biocel.2007.03.001
Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor ??-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines, Clinical Cancer Research, vol.10, issue.23, pp.8094-8104, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-1023
Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells, Molecular Cancer Research, vol.6, issue.12, pp.1908-1919, 2008. ,
DOI : 10.1158/1541-7786.MCR-08-0299
URL : https://hal.archives-ouvertes.fr/inserm-00351047
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells, Endocrine Related Cancer, vol.14, issue.4, pp.1021-1028, 2007. ,
DOI : 10.1677/ERC-07-0144
Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status, The International Journal of Biochemistry & Cell Biology, vol.41, issue.1, pp.225-234, 2009. ,
DOI : 10.1016/j.biocel.2008.08.019
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine , and epothilone B, Molecular Cancer Therapeutics, vol.2, issue.10, pp.971-984, 2003. ,
P21WAF1/CIP1 is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells, Oncogene, vol.23, issue.1, pp.21-29, 2004. ,
DOI : 10.1038/sj.onc.1207020
Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2, Clinical Cancer Research, vol.11, issue.17, pp.6382-6389, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0344
Release of Methyl CpG Binding Proteins and Histone Deacetylase 1 from the Estrogen Receptor ?? (ER) Promoter upon Reactivation in ER-Negative Human Breast Cancer Cells, Molecular Endocrinology, vol.19, issue.7, pp.1740-1751, 2005. ,
DOI : 10.1210/me.2004-0011
Recruitment of Distinct Chromatin-modifying Complexes by Tamoxifen-complexed Estrogen Receptor at Natural Target Gene Promoters in Vivo, Journal of Biological Chemistry, vol.279, issue.15, pp.15050-15058, 2004. ,
DOI : 10.1074/jbc.M311932200
Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling, Cancer Research, vol.68, issue.5, pp.1513-1519, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-2822
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor ?, International Journal of Cancer, vol.60, issue.33, pp.353-358, 2003. ,
DOI : 10.1002/ijc.11403
Estrogen Receptor-?? Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter, Cell, vol.115, issue.6, pp.751-763, 2003. ,
DOI : 10.1016/S0092-8674(03)00934-6
Molecular Determinants for the Tissue Specificity of SERMs, Science, vol.295, issue.5564, pp.2465-2468, 2002. ,
DOI : 10.1126/science.1068537
Recruitment of Histone Deacetylase 4 to the N-Terminal Region of Estrogen Receptor ??, Molecular Endocrinology, vol.19, issue.12, pp.2930-2942, 2005. ,
DOI : 10.1210/me.2005-0178
Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor, Circulation Research, vol.106, issue.1, pp.155-165, 2010. ,
DOI : 10.1161/CIRCRESAHA.109.207084
Association of Estrogen Receptor ?? and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells, Cancer Research, vol.69, issue.7, pp.2935-2940, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-3458
Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-?? Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90, Clinical Cancer Research, vol.13, issue.16, pp.4882-4890, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-3093
Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM, Molecular and Cellular Biology, vol.30, issue.2, pp.399-412, 2010. ,
DOI : 10.1128/MCB.00907-09
Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling, Carcinogenesis, vol.31, issue.3, pp.382-387, 2009. ,
DOI : 10.1093/carcin/bgp308
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1, Experimental Cell Research, vol.298, issue.2, pp.560-573, 2004. ,
DOI : 10.1016/j.yexcr.2004.04.038
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells, Oncogene, vol.23, issue.37, pp.6261-6271, 2004. ,
DOI : 10.1038/sj.onc.1207830
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma, Oncogene, vol.8, issue.29, pp.4609-4623, 2005. ,
DOI : 10.1016/S0006-2952(03)00509-4
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist, Proceedings of the National Academy of Sciences, vol.105, issue.32, pp.11317-11322, 2008. ,
DOI : 10.1073/pnas.0801868105
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice, Molecular Cancer Therapeutics, vol.8, issue.6, pp.1596-1605, 2009. ,
DOI : 10.1158/1535-7163.MCT-08-1004
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance, Cancer Biology & Therapy, vol.4, issue.9, pp.956-960, 2005. ,
DOI : 10.4161/cbt.4.9.1911
ER?? negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor, Journal of Cancer Research and Clinical Oncology, vol.14, issue.9, pp.883-890, 2008. ,
DOI : 10.1007/s00432-008-0354-x
Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks, Clinical Cancer Research, vol.15, issue.19, pp.6148-6157, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1039
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens, Journal of Molecular Endocrinology, vol.32, issue.2, pp.583-594, 2004. ,
DOI : 10.1677/jme.0.0320583
Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines, Journal of Biological Chemistry, vol.267, issue.25, pp.18008-18012, 1992. ,
Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor ??, in response to deacetylase inhibition by valproic acid and trichostatin A, Oncogene, vol.50, issue.31, pp.4894-4907, 2005. ,
DOI : 10.1210/me.9.4.443
URL : https://hal.archives-ouvertes.fr/hal-00016099
Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial ishikawa cells, Molecular Pharmacology, vol.68, issue.6, pp.1852-1862, 2005. ,
Minireview: Genomic Organization of the Human ER?? Gene Promoter Region, Molecular Endocrinology, vol.15, issue.12, pp.2057-2063, 2001. ,
DOI : 10.1210/me.15.12.2057
Trichostatin A and 5 Aza-2??? deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR, Breast Cancer Research and Treatment, vol.19, issue.1, pp.15-25, 2008. ,
DOI : 10.1007/s10549-007-9751-0
Estrogen Regulation of MicroRNA Expression, Current Genomics, vol.10, issue.3, pp.169-183, 2009. ,
DOI : 10.2174/138920209788185289
Control of estrogen receptor ligand binding by Hsp90, The Journal of Steroid Biochemistry and Molecular Biology, vol.72, issue.5, pp.223-230, 2000. ,
DOI : 10.1016/S0960-0760(00)00037-6
HSP90 and the chaperoning of cancer, Nature Reviews Cancer, vol.344, issue.10, pp.761-772, 2005. ,
DOI : 10.1038/nrc1716
Histone deacetylase inhibitor SAHA induces ER?? degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling, Biochemical Pharmacology, vol.75, issue.9, pp.1697-1705, 2008. ,
DOI : 10.1016/j.bcp.2007.10.035
Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein, Breast Cancer Research, vol.12, issue.2 R22, 2010. ,
Transcriptional activation of estrogen receptor ? in human breast cancer cells by histone deacetylase inhibition, Cancer Research, vol.60, issue.24, pp.6890-6894, 2000. ,
Valproic acid restores ER?? and antiestrogen sensitivity to ER??-negative breast cancer cells, Molecular and Cellular Endocrinology, vol.314, issue.1, pp.17-22, 2010. ,
DOI : 10.1016/j.mce.2009.09.011
Synergistic activation of functional estrogen receptor (ER)-? by DNA methyltransferase and histone deacetylase inhibition in human ER-?-negative breast cancer cells, Cancer Research, vol.61, issue.19, pp.7025-7029, 2001. ,
A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor ?? (ER) in ER negative human breast cancer cells in combination with 5-aza 2???-deoxycytidine, Breast Cancer Research and Treatment, vol.293, issue.3, pp.177-186, 2003. ,
DOI : 10.1023/A:1026146524737
Interaction of TFAP2C with the Estrogen Receptor-?? Promoter Is Controlled by Chromatin Structure, Clinical Cancer Research, vol.15, issue.11, pp.3672-3679, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2343
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation, Cancer Biology & Therapy, vol.6, issue.1, pp.64-69, 2007. ,
DOI : 10.4161/cbt.6.1.3549
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells, Breast Cancer Research and Treatment, vol.278, issue.2, pp.443-451, 2009. ,
DOI : 10.1007/s10549-008-0148-5
Epigenetic modifications of the estrogen receptor ? gene in epithelial ovarian cancer cells, Anticancer Research, vol.29, issue.1, pp.139-144, 2009. ,
DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines, The Prostate, vol.229, issue.2, pp.210-222, 2008. ,
DOI : 10.1002/pros.20673
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor ??-negative breast cancer cells to tamoxifen, Oncogene, vol.23, issue.9, pp.1724-1736, 2004. ,
DOI : 10.1038/sj.onc.1207315
ER?? and ER?? expression and transcriptional activity are differentially regulated by HDAC inhibitors, Oncogene, vol.60, issue.12, pp.1799-1806, 2006. ,
DOI : 10.1038/sj.onc.1209102
Post-translational modifications of??steroid receptors, Biomedicine & Pharmacotherapy, vol.60, issue.9, pp.520-528, 2006. ,
DOI : 10.1016/j.biopha.2006.07.082
p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation, Journal of Biological Chemistry, vol.275, issue.27, pp.20853-20860, 2000. ,
DOI : 10.1074/jbc.M000660200
Acetylation of Steroidogenic Factor 1 Protein Regulates Its Transcriptional Activity and Recruits the Coactivator GCN5, Journal of Biological Chemistry, vol.276, issue.40, pp.37659-37664, 2001. ,
DOI : 10.1074/jbc.M104427200
Direct Acetylation of the Estrogen Receptor alpha Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity, Journal of Biological Chemistry, vol.276, issue.21, pp.18375-18383, 2001. ,
DOI : 10.1074/jbc.M100800200
Acetylation of Estrogen Receptor ?? by p300 at Lysines 266 and 268 Enhances the Deoxyribonucleic Acid Binding and Transactivation Activities of the Receptor, Molecular Endocrinology, vol.20, issue.7, pp.1479-1493, 2006. ,
DOI : 10.1210/me.2005-0531
Regulation of Hormone-Induced Histone Hyperacetylation and Gene Activation via Acetylation of an Acetylase, Cell, vol.98, issue.5, pp.675-686, 1999. ,
DOI : 10.1016/S0092-8674(00)80054-9
GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1??, Cell Metabolism, vol.3, issue.6, pp.429-438, 2006. ,
DOI : 10.1016/j.cmet.2006.04.013
Acetylation of Nuclear Hormone Receptor-Interacting Protein RIP140 Regulates Binding of the Transcriptional Corepressor CtBP, Molecular and Cellular Biology, vol.21, issue.18, pp.6181-6188, 2001. ,
DOI : 10.1128/MCB.21.18.6181-6188.2001
HDAC1 Acetylation Is Linked to Progressive Modulation of Steroid Receptor-Induced Gene Transcription, Molecular Cell, vol.22, issue.5, pp.669-679, 2006. ,
DOI : 10.1016/j.molcel.2006.04.019
Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition, Nucleic Acids Research, vol.32, issue.6, pp.1957-1966, 2004. ,
DOI : 10.1093/nar/gkh524
Characterization of Four Autonomous Repression Domains in the Corepressor Receptor Interacting Protein 140, Journal of Biological Chemistry, vol.279, issue.15, pp.15645-15651, 2004. ,
DOI : 10.1074/jbc.M313906200
Ligand-dependent Formation of Retinoid Receptors, Receptor-interacting Protein 140 (RIP140), and Histone Deacetylase Complex Is Mediated by a Novel Receptor-interacting Motif of RIP140, Journal of Biological Chemistry, vol.276, issue.19, pp.16107-16112, 2001. ,
DOI : 10.1074/jbc.M010185200
Transcriptional Regulation by the Repressor of Estrogen Receptor Activity via Recruitment of Histone Deacetylases, Journal of Biological Chemistry, vol.279, issue.23, pp.24834-24843, 2004. ,
DOI : 10.1074/jbc.M312300200
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3, The EMBO Journal, vol.19, issue.16, pp.4342-4350, 2000. ,
DOI : 10.1093/emboj/19.16.4342
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC302030
The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3, Molecular and Cellular Biology, vol.21, issue.18, pp.6091-6101, 2001. ,
DOI : 10.1128/MCB.21.18.6091-6101.2001
SirT1 modulates the estrogen-insulin-like growth factor-1 signaling for postnatal development of mammary gland in mice, Breast Cancer Research, vol.9, issue.1 R1, 2007. ,
Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells, Breast Cancer Research and Treatment, vol.40, issue.23, pp.241-250, 2008. ,
DOI : 10.1007/s10549-007-9640-6
P21-Activated Kinase 1 Regulation of Estrogen Receptor-?? Activation Involves Serine 305 Activation Linked with Serine 118 Phosphorylation, Cancer Research, vol.66, issue.3, pp.1694-1701, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-2922
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells, Breast Cancer Research and Treatment, vol.278, issue.2, pp.443-451, 2008. ,
DOI : 10.1007/s10549-008-0148-5
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity, Cancer Research, vol.70, issue.9, pp.3647-3656, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-3360
-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer, Journal of Medicinal Chemistry, vol.53, issue.5, 2000. ,
DOI : 10.1021/jm901453q
URL : https://hal.archives-ouvertes.fr/hal-00159318